BR9503638A - Composto processo para sua produção e formulação farmacêutica - Google Patents
Composto processo para sua produção e formulação farmacêuticaInfo
- Publication number
- BR9503638A BR9503638A BR9503638A BR9503638A BR9503638A BR 9503638 A BR9503638 A BR 9503638A BR 9503638 A BR9503638 A BR 9503638A BR 9503638 A BR9503638 A BR 9503638A BR 9503638 A BR9503638 A BR 9503638A
- Authority
- BR
- Brazil
- Prior art keywords
- production
- pharmaceutical formulation
- compound process
- compound
- formulation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/38—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28995794A | 1994-08-12 | 1994-08-12 | |
| US33734994A | 1994-11-10 | 1994-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9503638A true BR9503638A (pt) | 1996-05-28 |
Family
ID=26965934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9503638A BR9503638A (pt) | 1994-08-12 | 1995-08-14 | Composto processo para sua produção e formulação farmacêutica |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5750566A (pt) |
| KR (1) | KR100375463B1 (pt) |
| BR (1) | BR9503638A (pt) |
| CO (1) | CO4410321A1 (pt) |
| UA (1) | UA43332C2 (pt) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US6413948B1 (en) | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL182285B1 (pl) * | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
| WO1996004901A1 (en) * | 1994-08-12 | 1996-02-22 | Eli Lilly And Company | Composition and method for treating anxiety |
| ZA969485B (en) * | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid receptor antagonists. |
| ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
| US6528271B1 (en) | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| US6124361A (en) * | 1997-12-31 | 2000-09-26 | Pfizer Inc | Bicyclo[3.1.0]hexanes and related compounds |
| EP1052246B1 (en) | 1998-01-28 | 2003-04-02 | Taisho Pharmaceutical Co., Ltd | Fluorine-containing amino acid derivatives |
| US6521561B1 (en) | 1998-05-01 | 2003-02-18 | President And Fellows Of Harvard College | Main-group metal based asymmetric catalysts and applications thereof |
| AU746806B2 (en) | 1998-08-31 | 2002-05-02 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo(3. 1.0)hexane derivatives |
| PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
| JP4505926B2 (ja) * | 1999-03-25 | 2010-07-21 | 大正製薬株式会社 | 新規カルボン酸誘導体及びその製造方法 |
| WO2000058258A1 (fr) * | 1999-03-25 | 2000-10-05 | Taisho Pharmaceutical Co., Ltd. | Nouveaux derives d'acide carboxylique et leur procede de production |
| JP4192331B2 (ja) * | 1999-04-16 | 2008-12-10 | 住友化学株式会社 | 光学活性２−オキソビシクロ［３．１．０］ヘキサン−６−カルボン酸誘導体の製造方法 |
| US7038077B2 (en) * | 2001-01-11 | 2006-05-02 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| EP1310482A1 (en) * | 2001-11-07 | 2003-05-14 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| NZ526050A (en) * | 2001-01-11 | 2005-03-24 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| US20040248963A1 (en) * | 2001-11-23 | 2004-12-09 | Bueno Melendo Ana Belen | Prodrugs of excitatory amino acids |
| US7456221B2 (en) * | 2001-12-21 | 2008-11-25 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| US20040116489A1 (en) * | 2002-02-12 | 2004-06-17 | Massey Steven Marc | Synthetic excitatory amino acids |
| US20030182669A1 (en) * | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
| US20050192273A1 (en) * | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| US7290215B2 (en) * | 2002-06-03 | 2007-10-30 | Microsoft Corporation | Dynamic wizard interface system and method |
| JP4792971B2 (ja) * | 2003-06-26 | 2011-10-12 | 大正製薬株式会社 | ２−アミノ−ビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸エステル誘導体 |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| US20070117789A1 (en) * | 2005-11-18 | 2007-05-24 | Astrazeneca Ab | Method of treatment |
| US20090093461A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Methods of Treating Anxiety and Mood Disorders |
| US20060217367A1 (en) * | 2004-07-01 | 2006-09-28 | Astrazeneca Ab | Method of treating anxiety disorders |
| US20060217366A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating schizophrenia and other disorders |
| ATE477803T1 (de) * | 2003-07-02 | 2010-09-15 | Astrazeneca Ab | Metabolit von quetiapine |
| US20090093460A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Compositions |
| US20060252743A1 (en) * | 2005-01-07 | 2006-11-09 | Astrazeneca Ab | Method of treating sleep disorders |
| US20060229292A1 (en) * | 2005-01-07 | 2006-10-12 | Astrazeneca Ab | Method of treating childhood disorders |
| EP1715921B1 (en) * | 2003-09-25 | 2013-04-24 | Abraxis BioScience, Inc. | Tetrahydroindolone derivatives for treatment of neurological conditions |
| JP4742239B2 (ja) * | 2003-11-07 | 2011-08-10 | 大正製薬株式会社 | ビシクロ［３．１．０］ヘキサン誘導体およびその中間体の製造方法 |
| US20050107439A1 (en) * | 2003-11-10 | 2005-05-19 | Helton David R. | Composition and method for treating emesis |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2009062134A1 (en) * | 2007-11-09 | 2009-05-14 | Cenomed Biosciences, Llc | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds |
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| US20110160184A1 (en) | 2008-06-20 | 2011-06-30 | Astrazeneca Ab | Dibenzothiazepine Derivatives and Use Thereof |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN119280233A (zh) | 2017-07-31 | 2025-01-10 | 诺华股份有限公司 | 玛沃谷兰在减少可卡因使用或预防复用可卡因中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3532744A (en) * | 1967-07-28 | 1970-10-06 | American Home Prod | 1- and 2-amino substituted indane and tetralene carboxylic acids |
| US3704312A (en) * | 1970-10-30 | 1972-11-28 | American Home Prod | Bialicyclic amino acids |
| US3746495A (en) * | 1971-06-01 | 1973-07-17 | American Home Prod | Anti-ulcer therapy |
| GB9325368D0 (en) * | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
-
1995
- 1995-06-29 US US08/496,643 patent/US5750566A/en not_active Expired - Fee Related
- 1995-06-29 US US08/496,642 patent/US5661184A/en not_active Expired - Fee Related
- 1995-08-12 KR KR1019950024891A patent/KR100375463B1/ko not_active IP Right Cessation
- 1995-08-14 CO CO95036221A patent/CO4410321A1/es unknown
- 1995-08-14 UA UA95083799A patent/UA43332C2/uk unknown
- 1995-08-14 BR BR9503638A patent/BR9503638A/pt active Search and Examination
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5985855A (en) * | 1996-09-27 | 1999-11-16 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using NAALADase inhibitors |
| US6004946A (en) * | 1996-09-27 | 1999-12-21 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US6413948B1 (en) | 1996-09-27 | 2002-07-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR960007545A (ko) | 1996-03-22 |
| CO4410321A1 (es) | 1997-01-09 |
| US5661184A (en) | 1997-08-26 |
| UA43332C2 (uk) | 2001-12-17 |
| US5750566A (en) | 1998-05-12 |
| KR100375463B1 (ko) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9503638A (pt) | Composto processo para sua produção e formulação farmacêutica | |
| BR9504509A (pt) | Composto processo para sua preparaçao e formulaçao farmaceûtica | |
| BR9505940A (pt) | Comprimido mastigável e processo para sua preparação | |
| BR9204361A (pt) | Composto e processo para sua preparacao formulacao farmaceutica e intermediario | |
| BR9612135A (pt) | Taxóides processo para sua preparação e composiç o farmacêutica | |
| BR9301137A (pt) | Composto,formulacao farmaceutica,sulfonamida e processo para sua preparacao | |
| BR9605354A (pt) | Composto composição farmacêutica processo para a produção do composto e uso | |
| BR9103195A (pt) | Composto e processo para sua preparacao | |
| BR9600821A (pt) | Composto formulação farmacêutica e processo para a preparação de um composto | |
| BR9408463A (pt) | Novos derivados de ginkgolide e processo para sua preparação | |
| BR9200951A (pt) | Compostos, processo para sua producao,preparacoes farmaceuticas e uso | |
| BR9004852A (pt) | Composto,processo para sua preparacao,sua aplicacao e composicao farmaceutica | |
| BR9610180A (pt) | Composição líquida autodepositante e processo para sua preparação | |
| BR9601275A (pt) | Compostos processo para sua preparação medicamentos preparação farmacêutica processo para sua produção e uso | |
| BR9602150A (pt) | Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso | |
| BR9708336A (pt) | Diidrato de eprosartan e processo para sua produção e formulação | |
| BR9506106A (pt) | Composto processo para sua preparação medicamento e composição farmacêutica | |
| BR9101121A (pt) | Composto,processo para sua preparacao,suas aplicacoes,e preparado farmaceutico | |
| BR9206950A (pt) | Composição farmacêutica e processo para sua preparação | |
| BR9602983A (pt) | Gel e processo para sua preparação | |
| BR9303456A (pt) | Compostos,processo para sua preparacao,medicamentos,processo para sua preparacao e emprego | |
| BR9301448A (pt) | Composicao e processo para sua preparacao | |
| BR9505962A (pt) | Suspensão farmacêutica aquosa e processo para sua preparação | |
| BR1100524A (pt) | Compostos, processo para sua preparação; compostos intermediários para os mesmos, e composições farmacêuticas | |
| BR9505109A (pt) | Compostos processo para sua preparaçao processo para produçao de uma preparaçao farmacêutica tal preparaçao e uso de tais compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |